JP6266642B2 - 皮膚炎治療 - Google Patents
皮膚炎治療 Download PDFInfo
- Publication number
- JP6266642B2 JP6266642B2 JP2015543453A JP2015543453A JP6266642B2 JP 6266642 B2 JP6266642 B2 JP 6266642B2 JP 2015543453 A JP2015543453 A JP 2015543453A JP 2015543453 A JP2015543453 A JP 2015543453A JP 6266642 B2 JP6266642 B2 JP 6266642B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- use according
- dermatitis
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000004624 Dermatitis Diseases 0.000 title claims description 46
- 238000011282 treatment Methods 0.000 title description 29
- 150000001875 compounds Chemical class 0.000 claims description 63
- 125000005647 linker group Chemical group 0.000 claims description 35
- 125000005842 heteroatom Chemical group 0.000 claims description 24
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 19
- 206010012442 Dermatitis contact Diseases 0.000 claims description 17
- 208000010247 contact dermatitis Diseases 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 8
- 201000008937 atopic dermatitis Diseases 0.000 claims description 8
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229960004716 idoxuridine Drugs 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 7
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- RBPYIYOPSGHFQG-IIFHDYRKSA-N 1,1,1-trifluoro-3-[(2e,6z,9z,12z,15z)-octadeca-2,6,9,12,15-pentaenyl]sulfanylpropan-2-one Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CC\C=C\CSCC(=O)C(F)(F)F RBPYIYOPSGHFQG-IIFHDYRKSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 11
- 230000005951 type IV hypersensitivity Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 9
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 8
- 229960002986 dinoprostone Drugs 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 8
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002085 irritant Substances 0.000 description 5
- 231100000021 irritant Toxicity 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 208000002029 allergic contact dermatitis Diseases 0.000 description 4
- 210000005069 ears Anatomy 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 208000001875 irritant dermatitis Diseases 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- -1 isopropanol Chemical compound 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005555 metalworking Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 235000014692 zinc oxide Nutrition 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- AQZRARFZZMGLHL-UHFFFAOYSA-N 2-(trifluoromethyl)oxirane Chemical compound FC(F)(F)C1CO1 AQZRARFZZMGLHL-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930188104 Alkylresorcinol Natural products 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010037898 Rash vesicular Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000012754 barrier agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008338 calamine lotion Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000006292 cyclic linker group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000003350 kerosene Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 208000002440 photoallergic dermatitis Diseases 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- WEMNATFLVGEPEW-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1.C=1C=CSC=1 WEMNATFLVGEPEW-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
R−L−CO−X (I)
(式中、Rは、S、O、N、SO、SO2から選択される1個以上のヘテロ原子またはヘテロ原子団により任意に中断されるC10-24不飽和炭化水素基であり、当該炭化水素基は、少なくとも4個の非共役二重結合を有し;
Lは、R基およびカルボニルCO間に1〜5個の原子で架橋する連結基であり、ここで、Lはこの連結基の骨格に少なくとも1個のヘテロ原子を有し;且つ、
Xは電子求引基である。)
R−L−CO−X (I)
(式中、Rは、S、O、N、SO、SO2から選択される1個以上のヘテロ原子またはヘテロ原子団により任意に中断されるC10-24不飽和炭化水素基であり、当該炭化水素基は、少なくとも4個の非共役二重結合を有し;
Lは、R基およびカルボニルCO間に1〜5個の原子で架橋する連結基であり、ここで、Lはこの連結基の骨格に少なくとも1個のヘテロ原子を有し;且つ、
Xは電子求引基である。)
上述のように、用語「皮膚炎」は、広範にわたるもので、さまざまな異なる皮膚疾患を含む。本発明の化合物は、さまざまな異なる状態の皮膚炎の治療に有用であり得ると考えられるが、この化合物は、アトピー性皮膚炎または接触皮膚炎の治療に使用されることが好ましい。
R−Y1−Y2−CO−X
の化合物である。
(式中、RおよびXは、先に定義した通りであり;
Y1が、O、S、NH、N(C1-6−アルキル)、SO若しくはSO2から選択されるか;
Y2が、(CH2)n若しくはCH(C1-6アルキル)であるか;または、
Y1およびY2が一緒になって、5員若しくは6員の複素の、随意不飽和若しくは芳香族の環を形成するか;または、
Y1が、5員若しくは6員の複素の、随意不飽和若しくは芳香族の環を形成し、Y2が(CH2)nであるかであり;
ここで、nは1〜3、好ましくは1である。)
RS(C1-6アルキル)CH2−COX+Z- (VI)
(ここで、RおよびXは、先に定義した通りであり、Zは、例えば、ハロゲン化物などの対イオンである。この化合物は、例えば、下記の化合物である。
(i)哺乳類において発症した疾患の臨床症状の出現を予防するかまたは遅延させること;
(ii)疾患を阻害すること、つまり、疾患の発症、またはその再発、またはその臨床症状もしくは亜臨床症状の少なくとも1つを停止、減少、または遅延させること;あるいは
(iii)疾患の臨床症状または亜臨床症状の1つ以上を軽減または減衰させること。
図1は、マウスのオキサゾロン誘発耳浮腫モデルに関して、AVX001の異なる治療濃度での右耳対左耳の厚さの絶対的増加を示す。
オキサゾロンを用いた皮膚感作の7日後に、オキサゾロンを用いて局所耳チャレンジを行うことによりDTHを誘発することができる。このチャレンジにより、24時間以内に耳に炎症反応が発生し、これは、抗原特異的T細胞に依存するものである。DTH反応は、さまざまな炎症細胞の動員および浮腫の発症を伴う。後者は、耳チャレンジ前後における耳の厚さの変化を定量化することにより測定することができる。
雌マウス(6〜8週、BALB/c)を、標準的な実験用マウスの餌、温度20〜24℃、湿度55%±10%、明期12時間/暗期12時間のサイクルで7日間順化させた。
第0日目:酸素と治療用空気1:1の混合気体中で、3〜4%イソフルランの吸入によりマウスに麻酔をかけた。腹部の皮膚を削り、100%アセトン中100μlの1.5%(w/v)オキサゾロンの局所適用を可能とした。
4グループ(1グループにつきマウス8匹)について観察した。
グループ1:プラシーボ、チャレンジの1時間後および7時間後
グループ2:化合物0.2重量%、チャレンジの1時間後および7時間後
グループ3:化合物0.05重量%、チャレンジの1時間後および7時間後
グループ4:化合物0.01重量%、チャレンジの1時間後および7時間後
第7日目:ミツトヨマイクロメータ(精度0.01mm)を用いて、耳チャレンジ直前に、両耳の厚さを測定した(1つの耳につき5回測定)。
耳の厚さの増加量(Δμm):
第8日目の厚さ(μm)-第7日目の厚さ(μm)
オキサゾロン特異的増加量(Δμm):
右耳における増加量(Δμm)-左耳における増加量(Δμm)
耳の厚さの相対的増加量(%):
(耳の厚さの増加量(Δμm)/第7日目の厚さ(μm))×100%
耳の厚さの相対的オキサゾロン特異的増加量(%):
右耳の相対的増加量(%)-左耳の相対的増加量(%)
プラシーボグループにおいては、エタノールでチャレンジした耳と比較して、オキサゾロンでチャレンジした耳の厚さは、95%という有意な(p<0.0001)増加が観察された。右耳の平均厚さは、第7日目の230μmから第8日目には447μmに増加した。
AVX001を用いた治療により、オキサゾロン特異的耳介腫脹は、217μm(プラシーボ)から134μm(0.01%AVX001)、103μm(0.05%AVX001)および94μm(0.2%AVX001)に減少した。AVX001によるオキサゾロン特異的耳介腫脹の減少は、全濃度に関し統計的に有意なものであった。
図3は、AVX処理耳組織対プラシーボ耳組織の耳組織PGE2濃度における有意な減少(20%)を示す。PGE2は、アラキドン酸の代謝物であり、結果は、阻害剤AVX001がその標的である酵素のグループIVa−PLA2に到達していることを示している。
(i)PGE2のEIA分析
プリセリーズ(PreCellys)ホモジナイザーを用いて、インドメタシン(indomethasin)10μMを含む400μlの溶解緩衝液中で右耳の生検材料をホモジナイズした。その溶解物は、次の処理まで−80℃で保管した。キットのプロトコル(ケイマンケミカルズ(Cayman Chemicals))に従い、耳ホモジネートのPGE2のEIA分析を実施した。血漿サンプルを、EIA緩衝液で1:60および1:180に希釈した。それらのサンプルを一晩ハイブリダイズした(18時間、4℃)。マルチスキャンプレートリーダー(アセント・ラボシステムズ(Ascent Labsystems)、OD550nm)を使用し、EIAプレートを読み取った。マルチスキャン用アセントソフトウエア、バージョン2.4.1を使用し、データを得た。パラフィン処理したプラシーボマウス(n=5匹のマウス)に対して、平均値±標準偏差としてPGE2の結果を示す。
グループのデータを一元配置分散分析により検定した後、個々のグループをダネット検定(Dunnets test)またはスチューデントのt検定と比較した。データは、特に指定のない限り、平均値±標準偏差として記載した。p<0.05の値を、有意とみなした。
Claims (17)
- 皮膚炎治療用の薬剤の製造における、式(I)の化合物またはその塩の使用。
R−L−CO−X (I)
(式中、Rは、S、O、N、SO、SO2から選択される1個以上のヘテロ原子またはヘテロ原子団により任意に中断されるC10-24不飽和炭化水素基であり、前記炭化水素基は、少なくとも4個の非共役二重結合を有し;
Lは、R基およびカルボニルCO間に1〜5個の原子の架橋を形成する連結基であり、ここで、Lは前記連結基の骨格に少なくとも1個のヘテロ原子を有し;且つ、
Xは電子求引基である。) - 前記炭化水素基Rが、5〜7個の二重結合を有する、請求項1に記載の使用。
- 前記炭化水素基Rにおいて、二重結合がカルボニル基と共役していない、請求項2に記載の使用。
- 前記炭化水素基Rにおいて、二重結合の全てがシス配置であるか、または、前記炭化水素基において、前記カルボニルに最も近い二重結合を除く全ての二重結合がシス配置である、請求項2または3に記載の使用。
- 前記R基が17〜19の炭素を含む、請求項1〜4のいずれかに記載の使用。
- 連結基Lが、任意の(化学的に有意な)順序で互いに組み合わされることで連結基を形成し得る−CH2−、−CH(C1-6アルキル)−、−N(C1-6アルキル)−、−NH−、−S−、−O−、−CH=CH−、−CO−、−SO−、または−SO2−を含む、請求項1〜5のいずれかに記載の使用。
- Lが、O、S、N、またはSOから選択される前記連結基の骨格に少なくとも1個のヘテロ原子またはヘテロ原子団を含む、請求項1〜6のいずれかに記載の使用。
- Lが、−NH2CH2、−NH(Me)CH2−、−SCH2−、−SOCH2−、2,4−チオフェンおよび2,5−チオフェンである、請求項1〜7のいずれかに記載の使用。
- Xが、O−C1-6アルキル、CN、OCO2−C1-6アルキル、フェニル、CHal3、CHal2H、CHalH2であって、ここでHalは、ハロゲン、例えば、フッ素、塩素、臭素またはヨウ素、好ましくはフッ素を表す、請求項1〜8のいずれかに記載の使用。
- XがCHal3、好ましくはCF3である、請求項1〜9のいずれかに記載の使用。
- 前記化合物が式(I’)を有する、請求項1〜11のいずれかに記載の使用。
R−Y1−Y2−CO−X (I’)
(式中、RおよびXは、先に定義した通りであり;
Y1が、O、S、NH、N(C1-6−アルキル)、SO若しくはSO2から選択されるか;
Y2が、(CH2)n若しくはCH(C1-6アルキル)であるか;または
Y1およびY2が一緒になって、5員若しくは6員の複素の、任意に不飽和若しくは芳香族の環を形成するか;または、
Y1が、5員若しくは6員の複素の、任意に不飽和若しくは芳香族の環を形成し、Y2が(CH2)nであり;
ここで、nは1〜3、好ましくは1である。) - 前記皮膚炎が接触皮膚炎またはアトピー性皮膚炎である、請求項1〜13のいずれかに記載の使用。
- 前記皮膚炎がアレルガン接触皮膚炎である、請求項1〜14のいずれかに記載の使用。
- 前記化合物を局所的に適用する、請求項1〜15のいずれかに記載の使用。
- 式(I)の化合物またはその塩を含む皮膚炎治療用組成物。
R−L−CO−X (I)
(式中、Rは、S、O、N、SO、SO 2 から選択される1個以上のヘテロ原子またはヘテロ原子団により任意に中断されるC 10-24 不飽和炭化水素基であり、前記炭化水素基は、少なくとも4個の非共役二重結合を有し;
Lは、R基およびカルボニルCO間に1〜5個の原子の架橋を形成する連結基であり、ここで、Lは前記連結基の骨格に少なくとも1個のヘテロ原子を有し;且つ、
Xは電子求引基である。)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1221329.4A GB201221329D0 (en) | 2012-11-27 | 2012-11-27 | Dermatitis treatment |
GB1221329.4 | 2012-11-27 | ||
PCT/EP2013/074612 WO2014082960A1 (en) | 2012-11-27 | 2013-11-25 | Dermatitis treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016500092A JP2016500092A (ja) | 2016-01-07 |
JP6266642B2 true JP6266642B2 (ja) | 2018-01-24 |
Family
ID=47560749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015543453A Expired - Fee Related JP6266642B2 (ja) | 2012-11-27 | 2013-11-25 | 皮膚炎治療 |
Country Status (9)
Country | Link |
---|---|
US (2) | US10085952B2 (ja) |
EP (1) | EP2925326A1 (ja) |
JP (1) | JP6266642B2 (ja) |
KR (1) | KR20150088302A (ja) |
CN (2) | CN110141562A (ja) |
AU (1) | AU2013351329B2 (ja) |
CA (1) | CA2892305A1 (ja) |
GB (1) | GB201221329D0 (ja) |
WO (1) | WO2014082960A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10539766B2 (en) | 2016-12-09 | 2020-01-21 | Seiko Epson Corporation | Projection optical system and projection image display device |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201221329D0 (en) * | 2012-11-27 | 2013-01-09 | Avexxin As | Dermatitis treatment |
GB201313238D0 (en) | 2013-07-24 | 2013-09-04 | Avexxin As | Process for the preparation of a polyunsaturated ketone compound |
GB201409363D0 (en) * | 2014-05-27 | 2014-07-09 | Avexxin As | Skin cancer treatment |
GB201501144D0 (en) | 2015-01-23 | 2015-03-11 | Avexxin As | Process for the preparation of a polyunsaturated ketone compound |
GB201604316D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
GB201609735D0 (en) * | 2016-06-03 | 2016-07-20 | Avexxin As | Combination therapy |
KR20190015320A (ko) * | 2016-06-03 | 2019-02-13 | 아벡신 에이에스 | 다중불포화 케톤 및 코르티코스테로이드를 포함하는 조합 치료요법 |
CA3025698A1 (en) * | 2016-06-03 | 2017-12-07 | Avexxin As | Combination therapy comprising a polyunsaturated ketone and a calcineurin inhibitor |
JP2019517525A (ja) * | 2016-06-03 | 2019-06-24 | アヴェクシン エーエス | 多価不飽和ケトン及びセコステロイドを含む併用療法 |
AU2017329957B2 (en) * | 2016-09-21 | 2020-05-07 | Avexxin As | Pharmaceutical composition |
GB201616088D0 (en) * | 2016-09-21 | 2016-11-02 | Avexxin As | Pharmaceutical composition |
CN110996931B (zh) * | 2017-06-16 | 2023-12-15 | 埃维克辛公司 | 用于治疗纤维化疾病的组合物和方法 |
GB202020843D0 (en) | 2020-12-31 | 2021-02-17 | Coegin Pharma Ab | Actinic keratosis treatment |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3689137B2 (ja) | 1994-08-19 | 2005-08-31 | 俊之 渡辺 | アレルギー性皮膚疾患治療用外用剤 |
JPH09143067A (ja) | 1995-11-27 | 1997-06-03 | Shiseido Co Ltd | アトピー性皮膚炎治療剤 |
WO1997038688A1 (en) * | 1996-04-12 | 1997-10-23 | Peptide Technology Pty. Limited | Methods of treating immunopathologies using polyunsaturated fattyacids |
JP2000095683A (ja) | 1998-09-28 | 2000-04-04 | Nof Corp | 皮膚外用剤 |
GB0202002D0 (en) | 2002-01-29 | 2002-03-13 | Leiv Eiriksson Nyotek A S | Use |
US20060216267A1 (en) * | 2002-08-20 | 2006-09-28 | Kovacs Stephen G | Hydrophobic elastomeric polymer chemistry device for inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis |
GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
US7652068B2 (en) | 2005-12-20 | 2010-01-26 | Cenestra Llc | Omega 3 fatty acid formulations |
FR2942719B1 (fr) * | 2009-03-04 | 2011-08-19 | Oreal | Utilisation de microorganismes probiotiques pour limiter les irritations cutanees |
GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
GB0909643D0 (en) | 2009-06-04 | 2009-07-22 | Avexxin As | Glomerulonephritis treatment |
CN103772312B (zh) * | 2009-10-02 | 2016-08-17 | 埃维克辛公司 | 抗炎症的2-羰基噻唑和2-羰基恶唑 |
US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
GB201014633D0 (en) | 2010-09-02 | 2010-10-13 | Avexxin As | Rheumatoid arthritis treatment |
GB201221329D0 (en) * | 2012-11-27 | 2013-01-09 | Avexxin As | Dermatitis treatment |
-
2012
- 2012-11-27 GB GBGB1221329.4A patent/GB201221329D0/en not_active Ceased
-
2013
- 2013-11-25 US US14/647,765 patent/US10085952B2/en not_active Expired - Fee Related
- 2013-11-25 CN CN201910439921.0A patent/CN110141562A/zh active Pending
- 2013-11-25 AU AU2013351329A patent/AU2013351329B2/en not_active Ceased
- 2013-11-25 EP EP13824489.2A patent/EP2925326A1/en not_active Ceased
- 2013-11-25 WO PCT/EP2013/074612 patent/WO2014082960A1/en active Application Filing
- 2013-11-25 CN CN201380061856.3A patent/CN104968349A/zh active Pending
- 2013-11-25 JP JP2015543453A patent/JP6266642B2/ja not_active Expired - Fee Related
- 2013-11-25 CA CA2892305A patent/CA2892305A1/en not_active Abandoned
- 2013-11-25 KR KR1020157016659A patent/KR20150088302A/ko active IP Right Grant
-
2018
- 2018-08-30 US US16/117,148 patent/US10758499B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10539766B2 (en) | 2016-12-09 | 2020-01-21 | Seiko Epson Corporation | Projection optical system and projection image display device |
Also Published As
Publication number | Publication date |
---|---|
US10758499B2 (en) | 2020-09-01 |
US20190167606A1 (en) | 2019-06-06 |
US10085952B2 (en) | 2018-10-02 |
AU2013351329A1 (en) | 2015-06-04 |
CA2892305A1 (en) | 2014-06-05 |
CN104968349A (zh) | 2015-10-07 |
EP2925326A1 (en) | 2015-10-07 |
US20150290144A1 (en) | 2015-10-15 |
AU2013351329B2 (en) | 2016-02-11 |
WO2014082960A1 (en) | 2014-06-05 |
GB201221329D0 (en) | 2013-01-09 |
JP2016500092A (ja) | 2016-01-07 |
CN110141562A (zh) | 2019-08-20 |
KR20150088302A (ko) | 2015-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6266642B2 (ja) | 皮膚炎治療 | |
JP3631259B2 (ja) | 医薬組成物 | |
JP5837481B2 (ja) | 糸球体腎炎治療 | |
JP2005518419A (ja) | ポリ不飽和ケトンを乾癬の治療に使用する方法 | |
KR20150025286A (ko) | 피토스핑고신-1-포스페이트 또는 그 유도체를 포함하는 아토피 또는 피부상처 치료 또는 예방용 조성물 | |
JPS62246515A (ja) | タモキシフエン又はその製薬上認容性塩を含有する乾癬の治療剤 | |
WO2017111069A1 (ja) | 止痒剤 | |
BR102012009350B1 (pt) | composição farmacêutica tópica, processo de produção da composição farmacêutica tópica e uso da composição farmacêutica tópica | |
JP2019517527A (ja) | 多価不飽和ケトン及びカルシニューリン阻害剤を含む併用療法 | |
WO2021242758A1 (en) | Improved nitro-fatty acid oral dose regimens | |
GB2391808A (en) | Lanolin hydrocarbon containing compositions from the reduction of lanolin or lanolin-derived feedstock | |
KR20150023607A (ko) | 에리오딕티올 화합물 또는 이의 약학적으로 허용되는 염을 유효성분으로 함유하는 접촉성 피부염 예방 또는 치료용 약학적 조성물 | |
JP2021504470A (ja) | N−アセチル又はn−アシルアミノ酸を含むアトピー又は痒み症治療用組成物 | |
JP2019517519A (ja) | 多価不飽和ケトン及びコルチコステロイドを含む併用療法 | |
JP2019514983A (ja) | エネルギー代謝を標的とする薬剤での活性化真皮状態の処置 | |
US9408844B2 (en) | Methods for treating inflammatory conditions | |
WO2024050431A2 (en) | Tapinarof and analogs thereof for use in treating ahr mediated diseases | |
AU2012321108B2 (en) | Treatment of seborrhoea | |
WO2024050434A1 (en) | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES | |
JP2021534257A (ja) | 新たな亜鉛錯体、その調製、ならびにヒトおよび動物疾患の治療のためのその使用 | |
JP2008509994A (ja) | 乾癬の治療のための組成物および方法 | |
Sitaram | Design of cream based formulation for skin psoriasis | |
NZ625852B2 (en) | Treatment of seborrhoea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161026 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171012 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171024 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171124 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6266642 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees | ||
S804 | Written request for registration of cancellation of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314803 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |